RESEARCH-USE BIOSIMILAR ANTIBODY
Regdanvimab
Monoclonal antibody · IgG1
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19.
TARGETSARS-CoV-2 Spike RBD
YMonoclonal antibody
CATALOGSC-BS-223
CATALOG NUMBERSC-BS-223
MOLECULAR WEIGHTApprox. 146.22 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19.
Regdanvimab is a recombinant research-use antibody directed against SARS-CoV-2 Spike RBD.